MICA*012:01Allele Facilitates the Metastasis of KRAS-Mutant Colorectal Cancer

被引:9
|
作者
Ding, Weifeng [1 ,2 ]
Ma, Yanyun [3 ]
Zhu, Weifeng [4 ]
Pu, Weilin [3 ]
Zhang, Jianfeng [5 ]
Qian, Fei [6 ]
Zhou, Youlang [7 ]
Deng, Yan [8 ]
Guo, Shicheng [9 ]
Wang, Jiucun [3 ,10 ,11 ]
Zhou, Xiaodong [2 ]
机构
[1] Nantong Univ, Dept Lab Med, Affiliated Hosp, Nantong, Peoples R China
[2] Univ Texas Houston, McGovern Med Sch, Houston, TX 77030 USA
[3] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] Nanchang Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Nanchang, Jiangxi, Peoples R China
[5] Nantong Univ, Dept Gastroenterol, Affiliated Hosp, Nantong, Peoples R China
[6] Nantong Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Nantong, Peoples R China
[7] Nantong Univ, Hand Surg Res Ctr, Dept Hand Surg, Affiliated Hosp, Nantong, Peoples R China
[8] Nanchang Univ, Dept Ophthalmol Children, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China
[9] Marshfield Clin Fdn Med Res & Educ, Ctr Precis Med Res, Res Inst, Marshfield, WI USA
[10] Fudan Univ, Inst Rheumatol Immunol & Allergy, Shanghai, Peoples R China
[11] Fudan Univ, Human Phenome Inst, Shanghai, Peoples R China
基金
中国国家自然科学基金;
关键词
MICA polymorphism; colorectal cancer; MICA*012; 01allele; immunosurveillance; tumor immunity; E-CADHERIN; MICA; NKG2D; OVEREXPRESSION; SUSCEPTIBILITY; POLYMORPHISM; STATISTICS; EXPRESSION; DISEASE; TUMOR;
D O I
10.3389/fgene.2020.00511
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Major histocompatibility complex (HLA) class I chain-related protein A (MICA) regulates immune surveillance through activation of NKG2D (natural killer group 2D) receptor. However, the genetic association, potential function, and predictive ability of MICA alleles with colorectal cancer (CRC) prognosis remain undefined. In this study, we characterized MICA alleles in tissue samples from 104 patients with CRC and 536 healthy controls and carried out genetic association studies by molecular and clinical CRC phenotypes. Preliminary sequence analysis revealed thatMICA*009:01or*049alleles were significantly decreased in patients with CRC (p= 0.0049), and further stratification analysis indicated thatMICA*012:01allele was associated with patients with CRC and carrying KRAS codon 12 mutation (p= 0.027). The functional consequences of MICA alleles were examined via transfected CRC cell lines which showed that overexpression ofMICA*012:01enhanced the proliferation, invasion, and metastatic phenotype of CRC. Preliminary analysis of disease-free survival time in patients with and withoutMICA*012:01suggest this allele may be predictive for poor prognosis of patients with KRAS codon 12 mutated CRC, as no somatic mutation of MICA gene was detected in CRC tumors compared to paracancerous tissues. Our study indicates thatMICA*012:01allele is associated with KRAS-mutated CRC, facilitates CRC invasion and metastasis, and possibly reduces the survival of patients with KRAS-mutated CRC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Genetic modifiers of KRAS-mutant colorectal cancer
    Tjader, Nijole P.
    Ramroop, Johnny
    Gandhi, Tanish
    Campbell, Peter T.
    Chan, Andrew T.
    Gallinger, Steven
    Giles, Graham G.
    Gunter, Marc J.
    Harrison, Tabitha A.
    Hoffmeister, Michael
    Newcomb, Polly A.
    Ogino, Shuji
    Phipps, Amanda I.
    Qu, Conghui
    Schoen, Robert E.
    Pellatt, Andrew
    Woods, Michael O.
    Van Guelpen, Bethany
    Stevens, Patrick
    Hampel, Heather
    Peters, Ulrike
    McElroy, Joseph P.
    Toland, Amanda E.
    CANCER RESEARCH, 2024, 84 (06)
  • [2] Dasatinib sensitizes KRAS-mutant colorectal cancer tumors to cetuximab
    Lisa Hutchinson
    Nature Reviews Clinical Oncology, 2011, 8 (4) : 193 - 193
  • [3] Personalizing KRAS-Mutant Allele-Specific Therapies
    Falcomata, Chiara
    Schneider, Guenter
    Saur, Dieter
    CANCER DISCOVERY, 2020, 10 (01) : 23 - 25
  • [4] Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
    Zhong, Longhui
    Wang, Rong
    Wang, Yanxia
    Peng, Shunli
    Ma, Yueyun
    Ding, Sijie
    Yang, Hong
    Chen, Shiyu
    Luo, Xiaoqing
    Wang, Wei
    NEOPLASIA, 2020, 22 (09): : 365 - 375
  • [5] Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
    Park, Sujeong
    Oh, Jinjoo
    Kim, Minhee
    Jin, Eun-Jung
    ANIMAL CELLS AND SYSTEMS, 2018, 22 (05) : 334 - 340
  • [6] PCSK9 IS A THERAPEUTIC TARGET IN KRAS-MUTANT COLORECTAL CANCER
    Wong, Chi Chun
    Wu, Jianlin
    Chan, Lam-Shing
    Ji, Fenfen
    Kang, Wei
    To, Ka Fai
    Sung, Joseph J.
    Yu, Jun
    GASTROENTEROLOGY, 2021, 160 (06) : S64 - S64
  • [7] ERK MAPK inhibition enhances the immunogenicity of KRAS-mutant colorectal cancer.
    Ryan, Meagan B.
    de la Cruz, Ferran Fece
    Ahronian, Leanne G.
    Phat, Sarah
    Myers, David T.
    Shahzade, Heather A.
    Hong, Catriona
    Corcoran, Ryan B.
    MOLECULAR CANCER RESEARCH, 2020, 18 (05) : 76 - 76
  • [8] Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer
    Alem, Diego
    Yang, Xinrui
    Beato, Francisca
    Sarcar, Bhaswati
    Tassielli, Alexandra F.
    Dai, Ruifan
    Hogenson, Tara L.
    Park, Margaret A.
    Jiang, Kun
    Cai, Jianfeng
    Yuan, Yu
    Fernandez-Zapico, Martin E.
    Tan, Aik Choon
    Fleming, Jason B.
    Xie, Hao
    MOLECULAR CARCINOGENESIS, 2023, 62 (07) : 1025 - 1037
  • [9] Ephrins/eph as novel synthetic lethal targets in Kras-mutant colorectal cancer
    Van Schaeybroeck, S.
    Allen, W. L.
    Dunne, P.
    Jithesh, P.
    Longley, D.
    Johnston, P. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Mouse Models of Kras-Mutant Colorectal Cancer: Valuable GEMMs for Drug Testing?
    Di Nicolantonio, Federica
    Bardelli, Alberto
    CLINICAL CANCER RESEARCH, 2013, 19 (11) : 2794 - 2796